Orexigen Therapeutics Inc (OREX) financial statements (2020 and earlier)

Company profile

Business Address 3344 N. TORREY PINES CT.
LA JOLLA, CA 92037
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments104214206177137
Cash and cash equivalents921551049878
Short-term investments11591017959
Restricted cash and investments90    
Receivables173  
Inventory, net of allowances, customer advances and progress billings23111
Inventory23111  
Prepaid expense and other current assets1
Deferred tax assets  1  
Other undisclosed current assets6211 
Total current assets:224234211178139
Noncurrent Assets
Property, plant and equipment11110
Intangible assets, net (including goodwill)76  
Intangible assets, net (excluding goodwill)76    
Restricted cash and investments00000
Other noncurrent assets3111
Total noncurrent assets:803220
TOTAL ASSETS:305237213180139
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4617151612
Accounts payable156454
Accrued liabilities3010774
Employee-related liabilities  554
Business combination, contingent consideration, liability15  
Deferred revenue and credits510833
Other undisclosed current liabilities 66310
Total current liabilities:6532302325
Noncurrent Liabilities
Liabilities, other than long-term debt1383773539
Deferred revenue and credits683763539
Deferred tax liabilities, net  1  
Other liabilities 000 
Business combination, contingent consideration, liability7  
Total noncurrent liabilities:1383773539
Total liabilities:781151075864
Stockholders' equity
Stockholders' equity attributable to parent5733224275
Common stock00000
Additional paid in capital698654574556512
Accumulated other comprehensive income (loss)40(0)(0)0
Accumulated deficit(645)(621)(552)(514)(437)
Total stockholders' equity:5733224275
Other undisclosed liabilities and equity170888480 
TOTAL LIABILITIES AND EQUITY:305237213180139

Income statement (P&L) ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues34245633
Revenue, net28111  
Cost of revenue
(Cost of Goods and Services Sold)
(8)    
Gross profit:26245633
Operating expenses(83)(85)(86)(81)(94)
Operating loss:(57)(60)(31)(77)(90)
Nonoperating income (expense)33(7)(7)(0)0
Investment income, nonoperating  000
Other nonoperating income (expense)33(7)(7)(0)0
Interest and debt expense18(7)(7)(1)(0)
Loss from continuing operations before equity method investments, income taxes:(6)(75)(45)(78)(90)
Other undisclosed income (loss) from continuing operations before income taxes(18)7   
Loss from continuing operations before income taxes:(24)(67)(45)(78)(90)
Income tax expense(0)(1)   
Net loss:(25)(69)(45)(78)(90)
Other undisclosed net income (loss) attributable to parent  70(0)
Net loss available to common stockholders, diluted:(25)(69)(38)(78)(90)

Comprehensive Income ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(25)(69)(45)(78)(90)
Comprehensive loss:(25)(69)(45)(78)(90)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent4070(0)
Comprehensive loss, net of tax, attributable to parent:(21)(68)(38)(78)(90)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: